Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Multidimensional Proteomic Approach of Endothelial Progenitors Demonstrate Expression of KDR Restricted to CD19 Cells.

Tytuł:
Multidimensional Proteomic Approach of Endothelial Progenitors Demonstrate Expression of KDR Restricted to CD19 Cells.
Autorzy:
Guerin CL; Innovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.; Cytometry Platform, Institut Curie, F-75006, Paris, France.; Department of Infection and Immunity, Luxembourg Institute of Health, Strassen, Luxembourg.
Guyonnet L; Innovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.; Cytometry Platform, Institut Curie, F-75006, Paris, France.; Department of Infection and Immunity, Luxembourg Institute of Health, Strassen, Luxembourg.
Goudot G; Vascular Medicine Department and Biosurgical Research Laboratory (Carpentier Foundation), AH-HP, Georges Pompidou European Hospital, Université de Paris, F-75015, Paris, France.
Revets D; Department of Infection and Immunity, Luxembourg Institute of Health, Strassen, Luxembourg.
Konstantinou M; Department of Infection and Immunity, Luxembourg Institute of Health, Strassen, Luxembourg.
Chipont A; Department of Infection and Immunity, Luxembourg Institute of Health, Strassen, Luxembourg.
Chocron R; PARCC, INSERM, Université de Paris, F-75006, Paris, France.; Emergency Department, AH-HP, Georges Pompidou European Hospital, F-75015, Paris, France.
Blandinieres A; Innovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.; Hematology Department and Biosurgical Research Laboratory (Carpentier Foundation), AH-HP, Georges Pompidou European Hospital, F-75015, Paris, France.
Khider L; Vascular Medicine Department and Biosurgical Research Laboratory (Carpentier Foundation), AH-HP, Georges Pompidou European Hospital, Université de Paris, F-75015, Paris, France.
Rancic J; Innovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.; Biosurgical Research Laboratory (Carpentier Foundation), AH-HP, Georges Pompidou European Hospital, F-75015, Paris, France.
Peronino C; Innovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.; Hematology Department and Biosurgical Research Laboratory (Carpentier Foundation), AH-HP, Georges Pompidou European Hospital, F-75015, Paris, France.
Debuc B; Innovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.; Plastic Surgery Department, AH-HP, Georges Pompidou European Hospital, F-75015, Paris, France.
Cras A; Innovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.; Cell therapy Unit, AP-HP, Saint Louis Hospital, F-75010, Paris, France.
Knosp C; PARCC, INSERM, Université de Paris, F-75006, Paris, France.
Latremouille C; Innovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.; Cardiovascular Surgery Department and Biosurgical Research Laboratory (Carpentier Foundation) AP-HP, Georges Pompidou European Hospital, F-75015, Paris, France.
Capel A; Carmat SA, Vélizy-Villacoublay, France.
Ollert M; Department of Infection and Immunity, Luxembourg Institute of Health, Strassen, Luxembourg.
Diehl JL; Innovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.; Biosurgical Research Laboratory (Carpentier Foundation), AH-HP, Georges Pompidou European Hospital, F-75015, Paris, France.; Intensive Care Department and Biosurgical Research Laboratory (Carpentier Foundation), AH-HP, Georges Pompidou European Hospital, F-75015, Paris, France.
Jansen P; Carmat SA, Vélizy-Villacoublay, France.
Planquette B; Innovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.; Biosurgical Research Laboratory (Carpentier Foundation), AH-HP, Georges Pompidou European Hospital, F-75015, Paris, France.; Respiratory Medicine department and Biosurgical Research Laboratory (Carpentier Foundation), AH-HP, Georges Pompidou European Hospital, F-75015, Paris, France.
Sanchez O; Innovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.; Biosurgical Research Laboratory (Carpentier Foundation), AH-HP, Georges Pompidou European Hospital, F-75015, Paris, France.; Respiratory Medicine department and Biosurgical Research Laboratory (Carpentier Foundation), AH-HP, Georges Pompidou European Hospital, F-75015, Paris, France.
Gaussem P; Innovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.; Hematology Department, AH-HP, Georges Pompidou European Hospital, F-75015, Paris, France.
Mirault T; PARCC, INSERM, Université de Paris, F-75006, Paris, France.; Vascular Medicine department, AH-HP, Georges Pompidou European Hospital, F-75015, Paris, France.
Carpentier A; Innovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.; Cardiovascular Surgery Department and Biosurgical Research Laboratory (Carpentier Foundation) AP-HP, Georges Pompidou European Hospital, F-75015, Paris, France.
Gendron N; Innovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.; Hematology Department and Biosurgical Research Laboratory (Carpentier Foundation), AH-HP, Georges Pompidou European Hospital, F-75015, Paris, France.
Smadja DM; Innovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France. .; Hematology Department and Biosurgical Research Laboratory (Carpentier Foundation), AH-HP, Georges Pompidou European Hospital, F-75015, Paris, France. .; European Hospital Georges Pompidou, Inserm UMR-S 1140, 20 rue Leblanc, 75015, Paris, France. .
Źródło:
Stem cell reviews and reports [Stem Cell Rev Rep] 2021 Apr; Vol. 17 (2), pp. 639-651. Date of Electronic Publication: 2020 Nov 17.
Typ publikacji:
Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: 2011- : [New York, NY] : Springer Science+Business Media
Original Publication: [Totowa, N.J.] : Humana Press, [2009]-
MeSH Terms:
Gene Expression Regulation*
Heart, Artificial*
Antigens, CD19/*metabolism
COVID-19/*metabolism
Endothelial Progenitor Cells/*metabolism
SARS-CoV-2/*metabolism
Vascular Endothelial Growth Factor Receptor-2/*metabolism
Endothelial Progenitor Cells/pathology ; Female ; Humans ; Male ; Middle Aged ; Proteomics
References:
Lancet. 2020 Feb 22;395(10224):565-574. (PMID: 32007145)
Ann Intensive Care. 2020 Jul 16;10(1):95. (PMID: 32676824)
Lancet. 2020 May 2;395(10234):1417-1418. (PMID: 32325026)
J Allergy Clin Immunol. 2020 Jul;146(1):211-213.e4. (PMID: 32333914)
Am J Physiol Heart Circ Physiol. 2003 Sep;285(3):H931-7. (PMID: 12915384)
Cell Rep. 2015 Mar 17;10(10):1708-1721. (PMID: 25772358)
Nat Med. 2013 Oct;19(10):1273-80. (PMID: 24037091)
Respir Res. 2020 Jul 28;21(1):198. (PMID: 32723327)
J Am Coll Cardiol. 2017 Jul 18;70(3):404-406. (PMID: 28705324)
J Thromb Haemost. 2019 Jul;17(7):1190-1194. (PMID: 31119878)
Stem Cell Rev Rep. 2021 Apr;17(2):694-699. (PMID: 32970229)
J Heart Lung Transplant. 2018 Jan;37(1):33-37. (PMID: 28986001)
Circ Res. 2016 Jun 10;118(12):1930-9. (PMID: 27073015)
Stem Cells Int. 2016;2016:7162160. (PMID: 28074098)
Cell. 2014 Apr 24;157(3):714-25. (PMID: 24766814)
Angiogenesis. 2013 Jan;16(1):147-57. (PMID: 22983452)
Cytotherapy. 2014 Feb;16(2):213-24. (PMID: 24280239)
Blood. 2018 Apr 5;131(14):1617-1621. (PMID: 29439955)
N Engl J Med. 2020 Jul 9;383(2):120-128. (PMID: 32437596)
N Engl J Med. 2005 Sep 8;353(10):999-1007. (PMID: 16148285)
J Thromb Haemost. 2020 Sep;18(9):2391-2399. (PMID: 32558198)
Arterioscler Thromb Vasc Biol. 2012 Apr;32(4):1045-53. (PMID: 22282356)
Nat Biotechnol. 2018 Dec 03;:. (PMID: 30531897)
Nat Biotechnol. 2011 Oct 02;29(10):886-91. (PMID: 21964415)
Stem Cell Rev Rep. 2021 Feb;17(1):4-8. (PMID: 32399806)
Circ Res. 2017 Jan 6;120(1):166-178. (PMID: 28057792)
Trends Immunol. 2012 Jul;33(7):323-32. (PMID: 22476049)
Cytometry A. 2017 Mar;91(3):254-260. (PMID: 28248454)
Angiogenesis. 2020 Nov;23(4):611-620. (PMID: 32458111)
Thromb Haemost. 2015 May;113(5):1084-94. (PMID: 25608764)
Physiol Rev. 2013 Oct;93(4):1743-802. (PMID: 24137021)
Science. 1999 Sep 3;285(5433):1553-8. (PMID: 10477517)
Grant Information:
SARCODO ANR and Fondation de France; mécénat crise COVID-19 - GHU APHP.CUP AP-HP
Contributed Indexing:
Keywords: Bioprosthetic total artificial heart; C-kit; COVID-19; Endothelial progenitors; Stem cells; VEGFR-2/KDR
Substance Nomenclature:
0 (Antigens, CD19)
0 (CD19 molecule, human)
EC 2.7.10.1 (KDR protein, human)
EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-2)
Entry Date(s):
Date Created: 20201118 Date Completed: 20210419 Latest Revision: 20220218
Update Code:
20231215
PubMed Central ID:
PMC7670993
DOI:
10.1007/s12015-020-10062-1
PMID:
33205351
Czasopismo naukowe
Endothelial progenitor cells (EPCs) are involved in vasculogenesis and cardiovascular diseases. However, the phenotype of circulating EPCs remains elusive but they are more often described as CD34 + KDR + . The aim of the study was to extensively characterize circulating potential vasculogenic stem cell candidates in two populations of patients with cardiovascular disease by powerful multidimensional single cell complementary cytometric approaches (mass, imaging and flow). We identified cellular candidates in one patient before and after bioprosthetic total artificial heart implantation and results were confirmed in healthy peripheral and cord blood by mass cytometry. We also quantified cellular candidates in 10 patients with different COVID-19 severity. Both C-TAH implantation and COVID-19 at critical stage induce a redistribution of circulating CD34 + and CD19 + sub-populations in peripheral blood. After C-TAH implantation, circulating CD34 + progenitor cells expressed c-Kit stem marker while specific subsets CD34 + CD133 -/+ CD45 -/dim c-Kit + KDR - were mobilized. KDR was only expressed by CD19 + B-lymphocytes and CD14 + monocytes subpopulations in circulation. We confirmed by mass cytometry this KDR expression on CD19 + in healthy peripheral and cord blood, also with a VE-cadherin expression, confirming absence of endothelial lineage marker on CD34 + subtypes. In COVID-19, a significant mobilization of CD34 + c-Kit + KDR - cells was observed between moderate and critical COVID-19 patients regardless CD133 or CD45 expression. In order to better evaluate EPC phenotype, we performed imaging flow cytometry measurements of immature CD34 + KDR + cells in cord blood and showed that, after elimination of non-circular events, those cells were all CD19 + . During COVID-19, a significant mobilization of CD19 + KDR + per million of CD45 + cells was observed between moderate and critical COVID-19 patients regardless of CD34 expression. CD34 + c-Kit + cells are mobilized in both cardiovascular disease described here. KDR cells in peripheral blood are CD19 positive cells and are not classic vasculogenic stem and/or progenitor cells. A better evaluation of c-Kit and KDR expressing cells will lead to the redefinition of circulating endothelial progenitors.Graphical abstract Central illustration figure. Multidimensional proteomic approach of endothelial progenitors demonstrate expression of KDR restricted to CD19 cells. Endothelial progenitor cells (EPCs) are involved in cardiovascular diseases, however their phenotype remains elusive. We elucidated here EPCs phenotype by a deep characterization by multidimensional single cell complementary cytometric approaches after Bioprosthetic total artificial heart implantation and during COVID-19. We showed a redistribution of circulating CD34 + and CD19 + sub-populations in both situations. None of the immature cell population expresses KDR. Mobilized CD34 + expressed c-Kit. Imaging flow cytometry demonstrated that CD34 + KDR + cells, after elimination of non-circular events, are all CD19 + . Our results suggest a new definition of circulating EPCs and emphasize involvement of CD19 cells in cardiovascular disease.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies